[HBsAg seroconversion after entecavir therapy for 7 years following a poor response to interferon-α 2b monotherapy in a HBeAg-negative patient with chronic hepatitis B]

Nan Fang Yi Ke Da Xue Xue Bao. 2016 Aug 20;36(9):1303-1304.
[Article in Chinese]

Abstract

We report a rare case of HBsAg seroconversion after 7 years of entecavir therapy in a 48-year-old HBeAg-negative CHB male patient with chronic hepatitis B (CHB). After a poor response to a 48-week interferon-α 2b therapy, the patient received long-term entecavir therapy. Serum ALT levels became normal and HBV DNA viral load was undetectable at the 10th week after commencement of entecavir treatment, and seroconversion of HBsAg was detected after 7 years of entecavir therapy.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • DNA, Viral / blood
  • Guanine / analogs & derivatives*
  • Guanine / therapeutic use
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B e Antigens / blood
  • Hepatitis B virus
  • Hepatitis B, Chronic / drug therapy*
  • Humans
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Seroconversion*
  • Treatment Outcome
  • Viral Load

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Interferon-alpha
  • entecavir
  • Guanine